ASXNotification regarding unquoted securities - MEM
other announcement
MEM
Pharmaceuticals, Biotechnology & Life Sciences
Memphasys
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 14 May 2021
- Reported shorts
- 9.1K
- Shares on issue
- 759.774M
Memphasys (MEM) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Proposed issue of securities - MEM
other announcement
Memphasys receives A$3.5 million from Peters Investments
other announcement
Potential Expedited FDA Pathway to US IVF Market
other announcement
Change of Director's Interest Notice
director_dealing announcement
KalkineWhy Did Memphasys (ASX:MEM) Draw ASX Growth Stocks Attention?
Highlights Memphasys Limited (ASX:MEM) has confirmed a european distribution agreement. The update keeps the stock in focus within Growth Stocks. Distribution agreements can extend a company's market reach into new regions without requiring it to build out its own local sales infrastructure. Memphasys is a biotechnology company developing cell separation technology, including applications in fertility treatment. The company has confirmed a european distribution agreement, a development that p...
Why is Memphasys (ASX:MEM) Back on the Radar After Its European Deal?
Highlights Memphasys Limited (ASX:MEM) has confirmed a european distribution agreement. The update keeps the stock in focus within Cannabis Stocks. Distribution agreements can extend a company's market reach into new regions without requiring it to build out its own local sales infrastructure. Memphasys is a biotechnology company developing cell separation technology, including applications in fertility treatment. The company has confirmed a european distribution agreement, a development that...
Memphasys Limited Grants 2.5 Million Unlisted Options to David Tasker Under Employee Incentive Plan
Memphasys Limited (ASX:MEM) has granted 2,500,000 unlisted options to David Tasker, or his nominee, following shareholder approval at the General Meeting held on 21 August 2026, as detailed in an ASX filing dated 18 September 2026. Key Points 2,500,000 unlisted options (ASX code: MEMAAE) issued to David Tasker on 18 September 2026 Options expire on 31 December 2027 with an exercise price of $0.007 Shareholder approval obtained under Resolution 4 of the Notice of General Meeting dated 22 July ...
Small CapsMemphasys Secures Exclusive Distribution Agreement with INVIDO LAB for Felix System
Memphasys nets exclusive Felix System deal with INVIDO LAB in Czech Republic, Slovakia, Kazakhstan; €416k min purchases, unlocking recurring cartridge revenue.
Application for quotation of securities - MEM
other announcement
Memphasys Secures European Felix Agreement
other announcement
Notification regarding unquoted securities - MEM
other announcement
Memphasys Investor Webinar Presentation - September 2026
other announcement
Felix Registration Achieved in Turkey, Sales Commence
other announcement
Notification of cessation of securities - MEM
other announcement
EUR526,500 Nordic Agreement Expands Felix European Footprint
other announcement
Appendix 4G and Corporate Governance Statement
other announcement
Google NewsInsiders Who Purchased AU$993.3k Of Memphasys Stock May Not Have Expected 17% Tumble - simplywall.st
Insiders Who Purchased AU$993.3k Of Memphasys Stock May Not Have Expected 17% Tumble simplywall.st
Felix Early Thai FDA Approval, Commercial Launch Accelerates
other announcement
Felix Registration Achieved in Vietnam and Cartridge Order
other announcement
Pivotal Felix Study Receives First Scientific Presentation
other announcement
European Commercial Roll-out continues with Poland Agreement
other announcement
Memphasys Limited Plans to Issue 8 Million Shares at $0.005 Each to Compensate Chapter One Advisors
Memphasys Limited has revealed a proposal to issue 8 million ordinary fully paid shares at a deemed price of $0.005 per share. This issuance aims to compensate Chapter One Advisors for their services, as detailed in the latest company update. Investors are likely to monitor this closely due to its potential impact on the company’s capital structure and future financing options. Key Points Memphasys Limited (MEM) Plans to issue 8 million shares to Chapter One Advisors as payment for services...
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Memphasys Enters into Consulting Agreement with Director
other announcement
Exclusive Thailand Commercialisation Agreement Secured
other announcement
UK Market Entry & Acceleration of Commercial Expansion
other announcement
Memphasys (ASX:MEM): $1.2m Capital Boost Puts This ASX Biotech Back in the Spotlight - Kalkine
Memphasys (ASX:MEM): $1.2m Capital Boost Puts This ASX Biotech Back in the Spotlight Kalkine
Successful $1.2M Placement and Convertible Note Extended
capital_raise announcement
Biotech Memphasys secures supply deal with Monash IVF for Felix sperm selection system
Sydney-based reproductive biotech Memphasys (ASX: MEM) has secured a 12-month exclusive national supply agreement with Monash IVF Group (ASX: MVF) to deploy its Felix automated sperm separation system across all 22 of the IVF provider's clinics on mainland Australia. The deal, described by Memphasys as the largest commercial arrangemen...
Memphasys Executes Supply Agreement with Monash IVF Group
other announcement
Why Memphasys (ASX:MEM) Shares Jumped 20% on Monday? - Kalkine
Why Memphasys (ASX:MEM) Shares Jumped 20% on Monday? Kalkine
South-East Asian Commercialization Agreement Secured
other announcement
Memphasys (ASX:MEM) books 1,800 of 2,500 Felix cartridges in two quarters - Stocks Down Under
Memphasys (ASX:MEM) books 1,800 of 2,500 Felix cartridges in two quarters Stocks Down Under
ITL Orders 1000 Felix Cartridges Across MENA Markets
other announcement
StockheadBiocurious: Is a recovery in gestation at IVF play Memphasys?
The developer of a sperm separation device for IVF purposes, Memphasys has disappointed investors for years. Is a rebirth in ... Read More The post Biocurious: Is a recovery in gestation at IVF play Memphasys? appeared first on Stockhead.
MENA Orders Secured, Expanded & Operations Unaffected
other announcement